Aurobindo Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Aurobindo Pharma Ltd reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.0%.
• Its expenses for the quarter were up by 5.4% QoQ and 6.1% YoY.
• The net profit increased 2.9% QoQ and increased 3.8% YoY.
• The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 14.61 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aurobindo Pharma Ltd is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients. The company operates in the pharmaceutical industry, which is characterized by a focus on research and development, regulatory compliance, and global distribution. Aurobindo Pharma has a diverse product portfolio that includes a range of oral and injectable generic formulations, over-the-counter products, and active pharmaceutical ingredients. The company is known for its extensive presence in both developed and emerging markets. Any recent major developments specific to Aurobindo Pharma Ltd are not available in the provided data.

Revenue

In the second quarter of the fiscal year 2026, Aurobindo Pharma Ltd reported a total income of ₹8,406.29 crores. This represents a quarter-over-quarter (QoQ) increase of 5.4% from ₹7,973.44 crores in the first quarter of FY26, and a year-over-year (YoY) increase of 6.0% from ₹7,932.07 crores in the second quarter of FY25. The consistent growth in total income suggests an upward trend in the company's revenue generation over the specified periods. The increase in revenue could be attributed to various factors such as higher sales volumes, new product launches, or expansion into new markets, although specific reasons are not provided in the available data.

Profitability

Aurobindo Pharma Ltd's profitability metrics for Q2FY26 show a profit before tax (PBT) of ₹1,274.26 crores, which is a 5.8% increase QoQ from ₹1,204.88 crores in Q1FY26, and a 5.6% increase YoY from ₹1,207.16 crores in Q2FY25. The company's tax expenses for Q2FY26 were ₹427.79 crores, showing an 11.8% rise QoQ, and a 9.5% rise YoY. Consequently, the profit after tax (PAT) for the quarter stood at ₹848.13 crores, reflecting a QoQ increase of 2.9% and a YoY increase of 3.8%. Earnings per share (EPS) for Q2FY26 was ₹14.61, up from ₹14.20 in Q1FY26 and ₹14.00 in Q2FY25, marking a 2.9% QoQ and a 4.4% YoY increase. These profitability metrics indicate consistent growth in the company's earnings over the reported periods.

Operating Metrics

During Q2FY26, Aurobindo Pharma Ltd's total expenses amounted to ₹7,132.03 crores, showing a 5.4% increase from ₹6,768.56 crores in Q1FY26 and a 6.1% rise from ₹6,724.91 crores in Q2FY25. The proportionate increase in expenses alongside revenue growth indicates operational scaling. The data reflects that despite an increase in tax expenses, the company has managed to maintain profitability with a stable increase in profit after tax and earnings per share. Detailed operating metrics such as P/E ratio, debt-to-equity ratio, or current ratio are not available in the provided data, which limits further analysis of the company's operational efficiency and financial health.